Kaveri Labs / Aranya Biotech: Accretive but Value-Destroying?
Kaveri Labs Ltd (KLL) is a listed formulations company with 5 crore shares, trailing PAT of ₹400 crore (EPS ₹80) and a market price of ₹1,200 - a P/E of 15. It has negotiated to acquire Aranya Biotech, an unlisted vaccine maker with 1.5 crore shares, PAT of ₹90 crore (EPS ₹60) and a standalone value of ₹900 per share, also 15 times earnings. KLL's advisers put the PV of post-tax synergies at ₹120 crore, but admit this rests on transferring two WHO pre-qualified products to Aranya's new facility, a milestone not yet cleared. Aranya's promoters have now demanded ₹1,020 per share, payable entirely in KLL shares. KLL's treasurer says it could instead borrow at 11% pre-tax (tax 25%) and pay cash without breaching its 1.8x debt/EBITDA covenant. The board wants to know whether the deal is accretive, whether it creates value, and whether cash or stock is the better currency.
1. At the demanded price of ₹1,020 per share settled in KLL stock, compute the exchange ratio, the post-merger EPS and the EPS accretion. Then determine whether the transaction creates or destroys value for KLL's shareholders, and explain why the two answers diverge.
Read the worked answer
Exchange ratio and share count
- Exchange ratio = Offer price ÷ Acquirer market price = 1,020 ÷ 1,200 = 0.85
- New shares issued = 1.5 crore × 0.85 = 1.275 crore
- Post-merger shares = 5 + 1.275 = 6.275 crore
Post-merger EPS
- Combined PAT (with synergy) = 400 + 90 + 120 = ₹610 crore
- EPS = 610 ÷ 6.275 = ₹97.21, against ₹80 pre-deal → accretion of 21.5%
- Without synergy: 490 ÷ 6.275 = ₹78.09, i.e. 2.4% dilution. Almost the entire accretion is synergy, not financial engineering.
Value test
- Consideration paid = 1.5 crore × ₹1,020 = ₹1,530 crore
- Maximum value of Aranya to KLL = standalone value ₹1,350 crore (90 × 15) + PV of synergy ₹120 crore = ₹1,470 crore
- Value transferred to Aranya's promoters = 1,530 − 1,470 = ₹60 crore destroyed
Cross-check through the merged entity: total value = 6,000 + 1,350 + 120 = ₹7,470 crore; KLL holders own 5 ÷ 6.275 = 79.68%, worth ₹5,952 crore, or ₹1,190 per share versus ₹1,200 today.
Why the divergence? KLL is paying 17 times Aranya's earnings (1,020 ÷ 60) for a business the market capitalises at 15 times, and the ₹120 crore of synergy is not large enough to bridge a ₹180 crore premium over standalone value. EPS accretion only says the acquired earnings exceed the after-tax financing cost - it says nothing about the price paid per rupee of earnings. Synergy-dependent accretion is the most common mask for overpayment.
2. What is the maximum price per share KLL can pay without destroying value for its own shareholders? Assuming KLL proceeds at ₹1,020, compare cash and stock financing on both EPS and value, and recommend a currency with reasons.
Read the worked answer
Maximum defensible price
KLL must retain at least ₹6,000 crore of the ₹7,470 crore merged value, i.e. an ownership of 6,000 ÷ 7,470 = 80.32%.
- 5 ÷ (5 + x) = 0.8032 → x = 1.225 crore new shares
- Ratio = 1.225 ÷ 1.5 = 0.8167 → price = 0.8167 × 1,200 = ₹980 per share
- Sanity check: 980 × 1.5 crore = ₹1,470 crore = standalone value + synergy. Any rupee above ₹980 is a transfer from KLL to Aranya.
Cash versus stock at ₹1,020
| Stock | Cash | |
|---|---|---|
| Consideration | 1.275 crore shares | ₹1,530 crore debt |
| Post-tax interest (11% × 0.75) | - | ₹126.2 crore |
| Combined PAT | ₹610.0 crore | ₹483.8 crore |
| Shares | 6.275 crore | 5.000 crore |
| EPS | ₹97.21 | ₹96.76 |
| Equity value | ₹5,952 crore | ₹5,940 crore |
| Value per share | ₹1,190.4 | ₹1,188.0 |
Recommendation: stock, marginally on both measures. The 20.32% of merged equity given up is worth ₹1,518 crore, slightly less than the ₹1,530 crore of cash. More importantly, the base case destroys ₹60 crore of value and the synergy is contingent on a regulatory milestone. Paying in stock makes Aranya's promoters co-owners of that risk and of the shortfall; paying cash leaves KLL holding 100% of a loss-making bet. Cash is defensible only if KLL is confident realisation will exceed ₹120 crore and wants to keep the excess, or if its shares are trading above intrinsic value.
3. Design a consideration structure that protects KLL against the synergy risk. State the specific mechanisms, the accounting/valuation treatment, and the two risks such a structure creates for KLL.
Read the worked answer
Structure
Split the ₹1,530 crore into a fixed and a contingent component, for example ₹1,050 crore (≈₹700 per share) paid at closing and ₹480 crore (≈₹320 per share) as a deferred earnout payable at the end of Year 2.
- Milestone definition. Earnout released only on (a) WHO pre-qualification of both named products at Aranya's new facility, and (b) achievement of a stated revenue or EBITDA threshold. Milestones must be objective, auditable and outside either party's unilateral control.
- Cap and floor. Cap the earnout at the stated ₹480 crore, with no acceleration, and a floor so KLL keeps some of the first rupee of synergy.
- Payment form. Settle the earnout in KLL shares issued at the then-prevailing 30-day VWAP, subject to a collar, so that the ultimate cost tracks KLL's own value.
- Governance. KLL retains operational control of the facility and the transfer programme; the earnout must not give promoters a veto over capex or product mix, otherwise KLL cannot run the business.
- Valuation. Because the earnout is contingent, its fair value at closing is a probability-weighted discounted amount, materially below ₹480 crore. Effectively, the headline ₹1,020 per share is not the economic price - the economic price is closer to the fixed ₹700 plus the option value, which is how the board should benchmark it against the ₹980 ceiling.
Risks created for KLL
- Incentive distortion - management chases the earnout metric (e.g. revenue) at the cost of margin or capital efficiency.
- Retention and disputes - promoter-managers hold leverage during the earnout period, and milestone disputes become litigation after integration has already happened. Earnouts also complicate tax treatment and post-deal integration.